Business Context and Reporting Period
This Form 8-K Current Report is filed by Cyclacel Pharmaceuticals, Inc. (not Bio Green Med Solution, Inc.) for the reporting period of January 25, 2010. The filing discloses the completion of a previously announced "registered direct" offering of securities to institutional investors.
Key Financial Metrics
- Offering Size: 2,350,000 units sold.
- Price per Unit: $2.50.
- Unit Composition: One share of common stock and one warrant to purchase 0.30 of a share.
- Net Proceeds: Approximately $5.4 million after deducting placement agent fees and offering expenses.
- Warrant Terms: Five-year term, exercisable after six months at an exercise price of $2.85 per share.
- Post-Offering Share Count: 31,398,820 shares of common stock issued and outstanding.
The filing does not provide data on revenue, profit, cash flow, operating margins, debt levels, or liquidity ratios beyond the proceeds from this specific transaction.
Material Changes
The primary material change is the increase in outstanding common stock and the infusion of capital resulting from the closing of the registered direct offering. The company's share count increased to 31,398,820 following the issuance of 2,350,000 new shares.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure that internet address information is not incorporated into the report. The transaction was facilitated by ROTH Capital Partners, LLC as the placement agent and Merriman Curhan Ford as the financial advisor.
Investor Verification Checklist
- Verify the exact net proceeds of $5.4 million against the gross proceeds ($5.875 million) to confirm the total fees and expenses deducted.
- Confirm the dilution impact of the 2,350,000 new shares and the potential future dilution from the 705,000 warrant shares (0.30 warrants per unit).
- Review the attached press release (Exhibit 99.1) for details on the intended use of the raised capital.
- Check subsequent filings to monitor the exercise of warrants and any further changes in the capital structure.